GENIL FINANCIAL STATEMENTS

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi — balance sheet, income statement and cash flow trends

GENILGen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi

🇹🇷 Turkey · IS · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue21.9 B ₺+16.3%

Gross Profit5.1 B ₺+39.6%

Operating Income2.6 B ₺+67.1%

EBITDA3.1 B ₺+55.5%

Net Income869.8 M ₺+146.6%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
GENIL	16.3%	23.4%	14.3%	4.0%
AMPH	-1.1%	47.3%	26.6%	11.0%
PCRX	4.6%	79.3%	16.1%	0.7%
IRWD	13.8%	99.6%	57.3%	28.3%
BHC	-9.9%	75.9%	60.0%	-13.5%
PAHC	26.0%	32.5%	15.0%	6.3%
Industry median	7.5%	60.6%	18.2%	4.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity11.7 B ₺53%
Current Liabilities9.1 B ₺41%
Long-term Liabilities1.5 B ₺7%

Key Figures

YoY change

Total Assets22.3 B ₺+57.1%

Total Liabilities10.6 B ₺+80.7%

Total Equity11.7 B ₺+40.6%

Cash & ST Investments1.4 B ₺+231.9%

Total Debt4.8 B ₺+152.0%

Net Debt4.5 B ₺+184.4%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
GENIL	1.33	41.0%	1.10	52.6%
AMPH	3.85	88.7%	2.05	46.9%
PCRX	4.73	62.9%	1.77	54.1%
IRWD	1.41	-275.1%	1.82	-50.0%
BHC	1.32	-1,010.0%	3.71	-8.4%
PAHC	3.17	217.6%	3.15	25.0%
Industry median	2.22	46.3%	1.24	45.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow1.4 B ₺-15.2%

Capital Expenditures-1 B ₺—

Free Cash Flow-1.5 B ₺-241.5%

Dividends Paid0 ₺—

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
GENIL	6.4%	-6.7%	4.8%	162.4%
AMPH	23.4%	18.8%	4.7%	213.2%
PCRX	19.4%	18.1%	1.3%	2,767.9%
IRWD	31.0%	31.0%	0.0%	109.8%
BHC	16.2%	11.3%	4.9%	-119.7%
PAHC	4.4%	0.9%	3.6%	69.4%
Industry median	15.2%	11.6%	2.5%	84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on GENIL

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 3, 26. This content is for informational purposes only and is not investment advice.